Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Histiocytoses are rare disorders of unknown origin with highly heterogeneous prognosis. BRAF mutations have been observed in Langerhans cell histiocytosis (LCH). We investigated the frequency of BRAF mutations in several types of histiocytoses. Histology from 127 patients with histiocytoses were reviewed. Detection of BRAF(V600) mutations was performed by pyrosequencing of DNA extracted from paraffin embedded samples. Diagnoses of Erdheim-Chester disease (ECD), LCH, Rosai-Dorfman disease, juvenile xanthogranuloma, histiocytic sarcoma, xanthoma disseminatum, interdigitating dendritic cell sarcoma, and necrobiotic xanthogranuloma were performed in 46, 39, 23, 12, 3, 2, 1, and 1 patients, respectively. BRAF status was obtained in 93 cases. BRAF(V600E) mutations were detected in 13 of 24 (54%) ECD, 11 of 29 (38%) LCH, and none of the other histiocytoses. Four patients with ECD died of disease. The high frequency of BRAF(V600E) in LCH and ECD suggests a common origin of these diseases. Treatment with vemurafenib should be investigated in patients with malignant BRAF(V600E) histiocytosis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1182/blood-2012-05-430140 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
F FDG PET/CT in a Rare Case of Erdheim-Chester Disease with Extensive Cutaneous and Skeletal Involvement.
Indian J Nucl Med
August 2025
Department of Haematology and Haemato-Oncology, Aster Medcity, Kochi, Kerala, India.
Erdheim-Chester disease (ECD) is a rare systemic non-Langerhans cell histiocytosis with multiple organ involvement. Being a rare disease with variable clinical manifestations, it is often difficult to diagnose. F-2-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) plays a vital role in assessing disease extent and severity, diagnosis, treatment response and is a potential biomarker for BRAF mutation.
View Article and Find Full Text PDF[Case report of Erdheim-Chester disease: a challenge for clinicians and radiologists].
Rofo
September 2025
Radiology, Brandenburg Medical School Theodor Fontane Ruppin Clinics, Neuruppin, Germany.
Multifocal intra-cranial masses: Late presentation of an uncommon histiocytic disorder.
Radiol Case Rep
November 2025
Loma Linda University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA.
We present a case of a 59-year-old female with headaches and memory loss. Her history includes surgeries for hydronephrosis and a mediastinal mass initially diagnosed as retroperitoneal fibrosis. Imaging performed a few years later revealed multiple bilateral supratentorial masses.
View Article and Find Full Text PDFCardiovascular Degeneration in Erdheim-Chester Disease: Prevalence, Burden, and Outcomes.
Blood Adv
August 2025
Mayo Clinic, Rochester, Minnesota, United States.
Erdheim-Chester Disease (ECD) is a rare systemic histiocytic neoplasm, with cardiac morbidities, including cardiovascular (CV) risk factors and cardiac conditions, playing a significant yet poorly understood role in disease burden. This study evaluated the prevalence, characteristics, and prognosis of ECD in patients with (ECD-C) and without (ECD-noC) cardiac involvement and compared the burden of cardiac morbidities with matched controls. Patients diagnosed with ECD between 1990 and 2021 at a tertiary center were included, with cardiac involvement centrally assessed using radiographic studies.
View Article and Find Full Text PDFUnraveling the molecular landscape of Erdheim-Chester disease: new insights from methylome and transcriptome integration.
Leukemia
August 2025
Institute of Parasitology and Biomedicine López-Neyra, Spanish National Research Council, Granada, Spain.
Erdheim-Chester Disease (ECD) is a rare histiocytosis characterized by a wide spectrum of clinical manifestations. Although somatic mutations have been involved in ECD, its etiology remains poorly understood. This study aimed to identify novel molecular mechanisms involved in ECD through the first integrated methylome and transcriptome analysis.
View Article and Find Full Text PDF